With the spotlight on therapeutic exploitation of GLP-1 mimetics, plus doubts about effectiveness of GIPR agonism in humans with T2D, early preclinical studies with stable GIPR agonists had until very recently [961] not progressed to clinical development. Here, GCG is linked to type 2 diabetes mellitus.